News MSD, AZ partner LaNova bought by Sino Biopharm for $951m LaNova Medicines is being bought out by minority shareholder Sino Biopharm in a deal valued at around $951 million.
R&D Allogeneic cell therapy isn’t dead, with Brian Culley Lineage Cell Therapeutics' Brian Culley discusses allogeneic cell therapy, even beyond the traditional cell therapy realm of oncology.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
